Aspira Women's Health Inc 8-K, filed Jan 6, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2021

Aspira Women’s Health Inc.

(Exact name of registrant as specified in its charter)



|  |  |  |

| --- | --- | --- | | Delaware | 001-34810 | 33-0595156 | | (State or other jurisdiction | (Commission | (IRS Employer | | of incorporation) | File Number) | Identification No.) |  |  | | --- |  | 12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas | 78738 | | --- | --- | | (Address of principal executive offices) | (Zip Code) | Registrant’s telephone number, including area code:  (512) 519-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|  |  |

| --- | --- | | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |  | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | --- | --- |  |  | | | --- | --- | | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |  |  | | | --- | --- | | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | 

Securities registered pursuant to Section 12(b) of the Act:

 |  | | | | --- | --- | --- | | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.001 per share | AWH | The Nasdaq Stock Exchange | 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





Item 7.01.  Regulation FD Disclosure.

In order to facilitate discussions with investors at an upcoming conference, Aspira Women’s Health Inc. is reporting that 3,849 OVA1 plus tests were performed in the three month period ending December 31, 2020, representing a 7% increase compared to the three month period ending September 30, 2020.  Ordering physicians were 2,615 for the three month period ending December 31, 2020, a 7% increase compared to the three month period ending September 30,  2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.











 |  | | Aspira Women’s Health Inc. | | --- | --- | --- | |  | | Aspira Women’s Health Inc. | |  | | | | Date: January 6, 2021 | By: | /s/ Robert Beechey | |  | | Robert Beechey | |  | | Chief Financial Officer |